Tratamiento mínimamente invasivo de los síntomas del tracto urinario inferior por hiperplasia benigna de próstata. Nuestra experiencia inicial con Urolift® bajo anestesia local y sedación

Objectives: Benign Prostatic Hyperplasia (BPH) is the most common cause of the Lower Urinary Tract Symptoms (LUTS) in ageing men. TURP is still the gold-standard procedure for the treatment of LUTS-BPH, however new minimally invasive modalities like Urolift procedure has been introduced. Methods: Patients with prostate size up to 100 g were offered both treatment modalities. Hundred patients were included in the study, 100 in TURP group (group A) and 100 in Urolift group (group B). International Prostate Symptom Score (IPSS) was used at initial contact and for evaluation of response to treatment. Group A underwent TURP under regional anaesthetic, while group B underwent Urolift under sedation. Results: The mean age in both groups was 66.4 years. The IPSS score improvement among both groups is attached in the diagram. Group B patients had less hospital stay, better erectile and ejaculatory function compared to group B, and no stress incontinence was detected in group B while 6.7% of the patients in group A suffered some stress incontinence. Conclusion: Urolift has the benefit of preserving the ejaculatory function and less complications. Nevertheless, it has size limitations and the IPSS score improvement is less satisfactory when compared to TURP.

show abstract

Analysis of outcome of prostatic UroLift placement in benign prostatic hyperplasia in a district hospital

Biswas,

Ahmed,

Soundararasha

et al. 2023

Journal of Clinical Urology

View full text Add to dashboard Cite

Aims and Objective: To analyse the outcome of prostatic UroLift (PUL) placement done at our hospital for the treatment of benign prostatic hyperplasia (BPH). Materials and Methods: Demographic and perioperative data were collected for all patients who underwent PUL placement for BPH at out hospital from December 2017 to January 2020. International prostate symptom score (IPSS), quality of life (QoL), maximum urinary flow rate (Q-max), complications and requirement of auxiliary procedures were noted till date. Mann–Whitney U test was used to compare the pre- and post-operative parameters. Results: A total of 45 patients underwent PUL placement and were followed up for a median period of 26 months (range 14–37 months). The median age of the patients and prostate volume were 76 years (range 54–90 years) and 50 mL (range 30–70 mL), respectively. Five patients had median lobe. An average of 3.2 ± 1.1 clips were placed. The mean IPSS, QoL and Q-max in the pre-operative and latest follow-up period were 19.3 ± 5.9 and 11.1 ± 5.6 ( p < 0.001), 4.3 ± 1.1 and 2.5 ± 1.4 ( p < 0.001), 9.8 ± 5.0 mL/s and 12.8 ± 6.2 mL/s ( p = 0.004), respectively. Complications were dysuria (one patient, 2.2%), urinary tract infection (one patient, 2.2%), haematuria (one patient, 2.2%), transient urinary retention (two patients, 4.4%), post-void dribbling (two patients, 4.4%), bladder stone (one patient, 2.2%) and clip migration (one patient 2.2%). Six patients (13.3%) required auxiliary treatment in follow-up. Conclusion: PUL placement improved the IPSS, QoL and Q-max significantly over a median follow-up of 26 months with retreatment rate of 13.3%. It is a safe procedure with few easily manageable complications. Level of evidence: Not applicable

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tratamiento mínimamente invasivo de los síntomas del tracto urinario inferior por hiperplasia benigna de próstata. Nuestra experiencia inicial con Urolift® bajo anestesia local y sedación

Cited by 3 publications

References 13 publications

Pharmacologic and Surgical Retreatment After Office-based Treatments for Benign Prostatic Hyperplasia: A Systematic Review

Pharmacologic and Surgical Retreatment After Office-based Treatments for Benign Prostatic Hyperplasia: A Systematic Review

Randomised controlled trial comparing safety and efficacy of Urolift to monopolar TURP

Analysis of outcome of prostatic UroLift placement in benign prostatic hyperplasia in a district hospital

Contact Info

Product

Resources

About